INTRODUCTION {#s1}
============

Lung cancer is the most common type of cancer and the leading global cause of cancer-related death \[[@R1], [@R2]\]. Non-small cell lung cancer (NSCLC) accounts for 80--85% of lung cancer cases. Although progress has been achieved in the past decades, the prognosis for NSCLC is still poor, with an estimated survival rate of only 15% at 5 years \[[@R1]\]. Several markers, including tumor stage, tobacco smoking \[[@R3]\], ki-67 expression \[[@R4]\], cyfra21-1 \[[@R5]\] and XRCC1 (X-ray repair cross-complementing protein 1) polymorphism \[[@R6]\] have been reported as prognostic indicators of outcomes in NSCLC patients. However, it is still difficult to predict patients' outcomes before treatment.

Mucin-1, previously called KL-6, EMA and CA15-3, is a glycoprotein present in normal epithelial tissue and in various cancers, including NSCLC \[[@R7], [@R8]\]. Mucin1 is capable of increasing the invasive and metastatic capability of tumor cells by reducing cell--cell adhesion \[[@R9]\] and cell-extracellular matrix adhesion \[[@R10]\]. Mucin1 can also interact with the family of epidermal growth factor receptors (EGFRs) and participate in the progression of carcinogenesis \[[@R11]\]. Therefore, Mucin1 has been extensively studied in a variety of neoplasms, including breast \[[@R12]\], gastric \[[@R13]\] and colorectal \[[@R14]\]. The first report of high MUC1 expression as a valuable prognostic marker for NSCLC was presented in 1998 \[[@R15]\]. Subsequently, numerous studies have been performed to validate this result \[[@R15]--[@R24]\], but it remains controversial \[[@R25]--[@R28]\]. A previous meta-analysis reported the prognostic value of high MUC1 expression in NSCLC patients \[[@R29]\] but included relatively few studies (*n* = 4). In addition, subgroup analysis based on ethnicity, method of detection and choice of therapy was not performed. Therefore, we conducted an updated meta-analysis to reappraise the effect of MUC1 expression on the prognosis of NSCLC patients.

RESULTS {#s2}
=======

Characteristics of eligible studies {#s2_1}
-----------------------------------

A total of 302 potentially relevant publications were identified after an initial search. After a review of the titles and abstracts, 278 studies were removed. Subsequently, 24 full-text articles were evaluated, seven studies were excluded for being out of scope \[[@R30]--[@R36]\] and another three were excluded because of insufficient data \[[@R37]--[@R39]\]. Miyazaki's study included two different survival analyses separately \[[@R20]\], resulting in a total of 15 eligible studies containing 1,682 patients that were included in this meta-analysis \[[@R15]--[@R28]\] (Figure [1](#F1){ref-type="fig"}). Studies that reported two endpoints were analyzed separately \[[@R17]--[@R19], [@R21], [@R22]\].

![Flow chart of study selection](oncotarget-08-90315-g001){#F1}

Fourteen studies investigated the prognostic role of MUC1 on overall survival (OS), and 5 studies explored the prognostic impact of MUC1 on progression-free survival (PFS). Nine studies were from Japan, three from China, two from Germany, and one from Greece. The sample sizes ranged from 41 to 185. HRs and 95% CIs were extracted directly from the 11 studies. HRs in 4 studies were estimated by Kaplan-Meier survival curves \[[@R15], [@R20], [@R23], [@R27]\]. MUC1 expression was divided into high and low levels, and different cut-off values were selected in each study. Most studies performed experiments using the manufacturer's instructions; some applied the median or mean levels as cut-off values, and the remaining studies defined the cut-off value independently or by using a ROC curve. Detailed characteristics of the included studies are listed in Table [1](#T1){ref-type="table"}.

###### Characteristics of studies included in this meta-analysis

  Author                  Year   Country   Ethnicity   Surgery   Chemotherapy     TNM        Study   HR         N     Biomarker   Method   Cutoff     High/low   Follow-up           NOS
  ----------------------- ------ --------- ----------- --------- ---------------- ---------- ------- ---------- ----- ----------- -------- ---------- ---------- ------------------- -----
  Tomita \[[@R16]\]       2016   Japan     Asian       Yes       NA               I--III     R       Reported   175   OS          ELISA    500 U/mL   15/160     NA                  5
  Shao \[[@R25]\]         2014   China     Asian       No        EGFR-TKI         IIIb--IV   P       Reported   114   PFS         ELISA    332 U/mL   NA         55                  7
  Li \[[@R17]\]           2014   China     Asian       No        EGFR-TKI         IIIb--IV   P       Reported   66    OS/PFS      RT-PCR   4.2        30/36      11.2 (8.4-16.6)     7
  Tanaka \[[@R18]\]       2012   Japan     Asian       Yes       Platinum-based   Ia--IIIa   R       Reported   103   OS/PFS      ECLIA    400 U/mL   23/80      NA                  8
  Situ \[[@R19]\]         2011   China     Asian       Yes       NA               Ib         R       Reported   178   OS/DFS      IHC      ROC        114/64     62.8 (3-157.1)      6
  Miyazaki1 \[[@R20]\]    2010   Japan     Asian       \-        NA               Ia--IV     R       SC         68    OS          ELISA    500 U/mL   50/18      NA                  6
  Miyazaki2 \[[@R20]\]    2010   Japan     Asian       \-        NA               Ia--IV     R       Reported   205   OS          ELISA    500 U/mL   69/136     NA                  6
  Kuemmel \[[@R26]\]      2009   Germany   Caucasian   \-        NA               Ia--IIIb   R       Reported   85    OS          IHC      IRS ≥ 3    44/41      48.1 (1.3--114.9)   7
  Woenckhaus \[[@R27]\]   2008   Germany   Caucasian   Yes       NA               Ia--IIIb   R       SC         96    OS          IHC      5%         73/23      35                  7
  Ishikawa \[[@R21]\]     2008   Japan     Asian       No        EGFR-TKI         IIIb--IV   R       Reported   70    OS/PFS      ECLIA    500 U/mL   35/35      NA                  8
  Fujiwara \[[@R22]\]     2008   Japan     Asian       No        EGFR-TKI         IIIa--IV   R       Reported   41    OS/PFS      ECLIA    500 U/mL   22/19      20.6                8
  Inata \[[@R28]\]        2007   Japan     Asian       \-        NA               Ia--IV     R       Reported   103   OS          ELISA    NA         34/69      NA                  6
  Tsutsumida \[[@R23]\]   2004   Japan     Asian       Yes       NA               NA         R       SC         185   OS          IHC      25%        45/140     NA                  6
  Hirasawa \[[@R24]\]     2000   Japan     Asian       No        Platinum-based   IIIb--IV   R       Reported   100   OS          ELISA    32 U/mL    11/19      54                  6
  Guddo \[[@R15]\]        1998   Greece    Caucasian   Yes       NA               Ia--IIb    R       SC         93    OS          IHC      25%        40/53      62 (45-74)          6

P: prospective; R: retrospective; NA: not available; OS: overall survival; PFS: progression-free survival; DFS: disease-free survival; SC: survival curve; ECLIA: electrochemiluminescence immunoassay; ELISA: enzyme-linked immunosorbent assay; IHC: immunohistochemistry; NOS: Newcastle-Ottawa score; ROC: receiver operating characteristic.

Results {#s2_2}
-------

MUC1 and OS {#s2_3}
-----------

Fourteen studies involving 1,568 patients investigated the association between MUC1 and OS \[[@R15]--[@R24], [@R26]--[@R28]\]. The pooled HR was 2.12 (95% CI: 1.47--3.05; *P* \< 0.001) (Figure [2](#F2){ref-type="fig"}), indicating that elevated MUC1 expression was significantly associated with poor OS. As heterogeneity was significant, a random-effects model was used (I^2^ = 75.7%; *P* \< 0.001). To detect potential heterogeneity, we conducted subgroup analysis by ethnicity, surgical intervention, chemotherapy regions, sample type, sample size and cut-off value (Table [2](#T2){ref-type="table"}). Subgroup analysis according to ethnicity indicated that elevated MUC1 expression had a significantly prognostic value in Asian populations (HR = 2.49; 95% CI = 1.73--3.59; *P* \< 0.001). In the subgroup analysis by sample type, a significantly worse OS was detected in the sera group (HR = 2.38; 95% CI = 1.47--3.82; *P* \< 0.001). When we conducted subgroup analysis by chemotherapy regions, a significant association was found in the EGFR-TKIs subgroup (HR = 3.16, 95% CI: 2.21--4.52, *P* \< 0.001) and in the platinum-based regimen subgroup (HR = 4.35, 95% CI: 2.45--7.72, *P* \< 0.001). Subgroup analyses suggested that elevated MUC1 expression predicted poor OS in patients with NSCLC, regardless of the sample size (\< 100 and ≥ 100) and status of surgical intervention (Yes and No).
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###### Meta-analysis results

                              No. of studies   No. of patients   HR (95% CIs)       Model    Heterogeneity test            
  --------------------------- ---------------- ----------------- ------------------ -------- -------------------- -------- ----------
  **OS**                                                                                                                   
  **Overall**                 14               1568              2.12 (1.47,3.05)   Random   53.48                75.70%   \< 0.001
  **Surgical intervention**                                                                                                
  Surgery                     6                830               2.61 (1.85,3.68)   Fixed    4.82                 0.00%    0.438
  Non-surgery                 4                277               3.34 (2.43,4.60)   Fixed    1.39                 0.00%    0.707
  **Chemotherapy**                                                                                                         
  EGFR-TKI                    3                177               3.16 (2.21,4.52)   Fixed    0.95                 0.00%    0.622
  Platinum-based              2                111               4.35 (2.45,7.72)   Fixed    0.06                 0.00%    0.814
  **Ethnicity**                                                                                                            
  Asian                       11               1294              2.49 (1.73,3.59)   Random   33.15                69.80%   \< 0.001
  Caucasian                   3                274               1.10 (0.45,2.73)   Random   9.18                 78.20%   0.01
  **Sample type**                                                                                                          
  Sera                        8                865               2.38 (1.47,3.82)   Random   29.11                76.00%   \< 0.001
  Tissue                      6                703               1.82 (0.97,3.44)   Random   24.15                79.30%   \< 0.001
  Sample size                                                                                                              
  Large                       7                1049              2.56 (1.72,3.82)   Random   13.12                54.30%   0.041
  Small                       7                519               1.71 (0.94,3.14)   Random   36.32                83.50%   \< 0.001
  **Cutoff value**                                                                                                         
  500 U/ml                    5                559               2.20 (1.19,4.10)   Random   18.71                78.60%   0.001
  **PFS**                                                                                                                  
  **Overall**                 5                394               2.00 (1.53,2.62)   Fixed    6.04                 33.80%   0.196

OS: overall survival; HR: hazard ratio; CI: confidence interval; OS: overall survival; PFS: progression-free survival.

MUC1 and PFS {#s2_4}
------------

Five studies comprising 394 patients evaluated the association between MUC1 expression and PFS \[[@R17], [@R18], [@R21], [@R22], [@R25]\]. The results indicated that high MUC1 expression was associated with poor PFS (HR = 2.00, 95% CI: 1.53--2.62, *P* \< 0.001) (Figure [3](#F3){ref-type="fig"}), without significant heterogeneity (I^2^ = 33.80%, *P* = 0.196).
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MUC1 and clinicopathological parameters {#s2_5}
---------------------------------------

Eight studies examined the relevance between MUC1 expression and the clinical features of NSCLC \[[@R16]--[@R19], [@R21], [@R22], [@R24], [@R27]\]. Pooled data revealed that elevated MUC1 expression was significantly related to performance status (≥ 2 vs. \< 2; OR = 2.32, 95% CI: 1.13--4.73, *P* = 0.021). However, no significant association was found with gender (male vs. female), age (≥ 65 vs. \< 65), smoking history (yes vs. no), tumor size (\> 3 cm vs. ≤ 3 cm), histology (AD vs. no-AD), and lymph node metastasis (yes vs. no). Some clinical features such as differentiation, TNM stage and distant metastasis were not included in our analysis due to a lack of data. The details of our analysis are shown in Table [3](#T3){ref-type="table"}.

###### Meta-analysis of the association between MUC1 and the clinicopathological features of NSCLC

  Characteristics                          No. of studies   No. of patients   OR (95% CI)        *P*     Heterogeneity   
  ---------------------------------------- ---------------- ----------------- ------------------ ------- --------------- ----------
  **Gender (male vs. female)**             8                829               1.32 (0.92,1.89)   0.13    17.70%          0.29
  **Age (≥ 65 vs. \< 65)**                 3                456               1.72 (0.65,4.58)   0.277   54.90%          0.109
  **Smoking history (yes vs. no)**         4                385               1.47 (0.88,2.45)   0.143   44.90%          0.142
  **Tumor size (\> 3 cm vs. \< 3 cm)**     3                374               1.00 (0.54,1.86)   0.993   19.10%          0.29
  **Histology (AD vs. no-AD)**             8                829               1.25 (0.52,3.02)   0.618   77.50%          \< 0.001
  **Lymph node metastasis (yes vs. no)**   3                374               1.24 (0.64,2.41)   0.53    31.50%          0.232
  **Performance status (≥ 2 vs. \< 2)**    3                177               2.32 (1.13,4.73)   0.021   0.00%           0.435

OR: odds ratio; CI: confidence interval; AD: adenocarcinoma; P~h~: P~heterogeneity.~

Publication bias {#s2_6}
----------------

Begg's funnel plot and the Egger's linear regression test were conducted to evaluate publication bias in the literature. No significant publication bias was detected by both Begg's test (*P* = 0.208 for OS and *P* = 0.327 for PFS) and the Egger's test (*P* = 0.604 for OS and *P* = 0.514 for PFS) (Figure [4](#F4){ref-type="fig"}). Therefore, no evidence of publication bias was noted.
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Sensitive analysis {#s2_7}
------------------

We adopted the "leave-one-out" scheme (i.e., the analysis is conducted using all studies except one) to explore the influence of individual studies on the pooled HRs. The results showed that the pooled HRs were not materially altered, which suggested that no individual study significantly affected the pooled results (Figure [5](#F5){ref-type="fig"}).

![Sensitivity analysis of the meta-analysis\
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DISCUSSION {#s3}
==========

To the best of our knowledge, only one meta-analysis on the prognostic value of MUC1 expression in NSCLC had previously been performed \[[@R29]\]. Our meta-analysis included three times more patients than the previous study, and the studies included in our analysis used more detailed information and patients with longer follow-up intervals. As a result, we were able to obtain more relevant results.

Our meta-analysis combined the results from 15 individual studies with 1,682 NSCLC patients and found that MUC1 overexpression had significantly prognostic value for OS (HR = 2.12, 95% CI: 1.47--3.05; *P* \< 0.001) and PFS (HR = 2.00, 95% CI: 1.53--2.62, *P* \< 0.001) in NSCLC patients. This link was observed in both surgical and non-surgical treatment groups. Subgroup analysis by ethnicity indicated the result was significant for the Asian subgroup (HR = 2.49, 95% CI: 1.73--3.59, *P* \< 0.001), but not for the Caucasian subgroup (HR = 1.10, 95% CI: 0.45--2.73, *P* = 0.832). Considering the limited number of Caucasian patients in our analysis, more studies should be conducted. When stratified by sample type, a significant risk was found in the sera group (HR=2.38, 95% CI: 1.47--3.82, *P* \< 0.001), indicating that MUC1 may be a convenient tumor marker for use in clinical practice. We found that 500 U/ml is the most frequently used cut-off value and is associated with significant risk (HR = 2.20, 95% CI: 1.19--4.10, *P* = 0.012).

We verified the poor prognostic role of high MUC1 expression in patients treated with a platinum-based regimen (HR=4.35, 95% CI: 2.45--7.72, *P* \< 0.001) or EGFR-TKIs (HR = 3.16, 95% CI: 2.21--4.52, *P* \< 0.001). Platinum-based chemotherapy has been widely adopted for the treatment of NSCLC patients and significantly improves survival and quality of life \[[@R40]\]. However, its efficacy varies among individuals \[[@R41]\]. The prognostic or predictive roles of a series of tumor markers were reported in NSCLC patients treated with platinum-based chemotherapy \[[@R42], [@R43]\], but until now, none was recommended for clinical practice. Based on our results, MUC1 might be a promising biomarker. EGFR-TKI therapy significantly improves the survival of NSCLC patients who harbor an EGFR mutation \[[@R44]\]. Unfortunately, there is no indicator that predicts the efficacy of EGFR-TKI therapy. Our findings indicate that MUC1 may be such an indicator, but as the sample size of our analysis is limited, large-scale prospective studies are needed to further confirm our results.

There are some limitations to our meta-analysis. First, the heterogeneity was moderately significant in the pooled HRs of OS (I^2^ = 75.7%, *P* \< 0.001). Although we performed subgroup analysis and sensitivity analysis to find the source of heterogeneity, none could completely explain it. Second, this meta-analysis was limited to articles published in English or Chinese, indicating that language bias likely existed. Third, most of the studies selected were conducted on Asian populations; thus, standardized analyses should be used to apply our results to other populations. Fourth, several HRs were extracted from Kaplan-Meier curves, which might have biased our results. Finally, NSCLC consists of several subtypes, such as adenocarcinoma, squamous cell carcinoma and others. The prognosis and selection of therapy for each type are dissimilar, but detailed information on NSCLC subtypes was lacking, and we did not conduct subgroup analysis by subtypes. More studies on the association between MUC1 and NSCLC subtypes are needed.

In conclusion, our results indicate that high MUC1 expression may be a marker of poor prognosis in NSCLC patients and a promising therapeutic target. Large, well-designed prospective studies are needed to confirm our findings.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We performed a literature search in PubMed, EMBASE, and CNKI (Chinese National Knowledge Infrastructure) databases using the following keywords: "MUC1", "Mucin1", "CA15-3", "CD227", "KL-6", "non-small cell lung cancer", "NSCLC", "prognosis", "survival", and "outcome". The most recent article found was published on January 13, 2017. The references of all publications and reviews were also manually searched to identify relevant studies.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

All included studies had to meet the following criteria: (1) evaluation of the association between MUC1 expression and NSCLC prognosis; (2) case-control studies; (3) sufficient data for estimating the hazard ratio (HR) with a 95% confidence interval (CI). The major reasons for exclusion were (1) duplicate studies; (2) case reports, comments or review articles; (3) studies lacking detailed data.

Data extraction {#s4_3}
---------------

Two investigators (XH and QS) performed searches and identified articles independently using a standard approach \[[@R45]\]. The following information was extracted: first author, publication year, nationality, ethnicity, quantitative method, cut-off value, follow-up months, hazard ratios (HR) with corresponding 95% confidence intervals (CI) for overall survival (OS) or progression-free survival (PFS) and the total number of participants, respectively. In case of discrepancies, another investigator (CC) was invited to check and discuss the original data until a consensus was reached. Quality assessment for each study included in the final analysis was performed by the same two reviewers according to the Newcastle-Ottawa quality assessment scale (NOS) \[[@R46]\]. NOS scores ranged from 0 to 9, and a score ≥ 6 indicates good quality in the present study.

Statistical analysis {#s4_4}
--------------------

The intensity of the relationship between MUC1 expression and survival was expressed as HRs, and the strength of the association between MUC1 and clinical parameters was expressed as an odds ratio (OR). In some studies, HR and the 95% CI were directly obtained using univariate or multivariate survival analysis. Otherwise, a method reported by Tierney was used to reconstruct the HR and its variance from Kaplan--Meier survival curves \[[@R47]\]. Heterogeneity among eligible studies was estimated using a Chi-square-based *Q* test and considered statistically significant when I^2^ \> 50% or *P* \< 0.1 \[[@R48]\]. A fixed effects model (Mantel-Haenszel method) was used if there was no significant heterogeneity; otherwise, a random effects model (Der Simonian and Laird method) was used \[[@R49]\]. Publication bias was evaluated using Egger's test and Begg's test, and *P* \< 0.05 was considered significant \[[@R50]\]. All statistical tests were conducted with STATA software version 12.0 (STATA Corporation, College Station, TX, USA) and *P* \< 0.05 was considered significant.

**Author contributions**

This study was conceived of and designed by XH. The data were extracted and analyzed by XH and QS. XH and CC wrote the manuscript. This manuscript was approved by all of the authors prior to submission.

This research was supported by the Jiangsu Provincial Six Talent Peak of Human Affairs Hall Funding (No.WSW-037), the Jiangsu Cancer Hospital Research Fund for Medical Sciences (ZQ201506) and the National Science Foundation for Young Scholars (No. 81302013).

**CONFLICTS OF INTEREST**

None declared.
